Epigenetic Testing for Breast Cancer Risk Stratification
Abstract
DNA methylation is increasingly recognized as an early molecular change in benign epithelium that is implicated in the development of high risk preneoplasia and cancer. Using a genome-wide screen we have previously identified methylation markers optimized for RP-FNA samples with potential for tissue-based breast cancer risk stratification. Most methylation markers are most relevant to ER-POS breast cancer. We have thoroughly assessed 12 new markers in an archival RP-FNA and cancer FNA sample set derived from 180 women. VCAN was identified as a gene preferentially methylated in ER-POS breast cancer and IRF7 as a gene preferentially methylated in ER-NEG breast cancer. We have now assembled a 7 marker panel with good coverage of ER-POS and ER-NEG breast cancer for assessment in prospectively acquired RP-FNA and cancer FNA samples. In addition, validation of an RP-FNA-based approach to risk stratification has been hampered by the lack of an unselected unaffected control cohort. We are rapidly expanding a community-based RP-FNA sample repository that provides an ideal unselected unaffected control cohort for validation of our panel in the coming year.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2012
- Accession Number
- ADA582383
Entities
People
- David Euhus
Organizations
- University of Texas Southwestern Medical Center